<?xml version="1.0" encoding="UTF-8"?>
<p>RSV is a single-stranded RNA enveloped virus belonging to the recently named 
 <italic>Pneumoviridae</italic> family, Orthopneumovirus genus, which causes lower respiratory tract illness [
 <xref rid="B88-vaccines-07-00168" ref-type="bibr">88</xref>,
 <xref rid="B89-vaccines-07-00168" ref-type="bibr">89</xref>]. Infection does not confer immunity to upper respiratory tract reinfection. The peak of severe disease is among infants in the first 3 months of life [
 <xref rid="B90-vaccines-07-00168" ref-type="bibr">90</xref>]. Prematurity, low birth weight, male sex, broncho-pulmonary dysplasia, congenital heart disease, immunodeficiency, cerebral palsy, and Down’s syndrome are risk factors for severe RSV bronchiolitis, but 50–80% of emergency admissions occur in otherwise healthy infants born at term [
 <xref rid="B90-vaccines-07-00168" ref-type="bibr">90</xref>]. Worldwide, RSV disease in children under the age of 5 years accounts for an estimated 33.8 million lower respiratory tract infections, 3.4 million hospitalizations, and up to 200,000 deaths annually [
 <xref rid="B90-vaccines-07-00168" ref-type="bibr">90</xref>].
</p>
